Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry

University of Bologna

Status: Enrolling

Conditions: Cancer Related Cardiovascular Toxicity

Treatments: Combination Product: Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06086132

ISACS CARDIONCO-PREDICT

Details and patient eligibility

About

This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction

Enrollment: 10,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years old or older
• Capable of giving informed consent
• Diagnosis of cancer scheduled for treatment according to treating physician's discretion
• Life expectancy >1 year
• For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs

Exclusion criteria

• Age <18 years old
• Not able to give informed consent
• Life expectancy <1 year
• Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's

Trial design

10,000 participants in 2 patient groups

Breast cancer

Description:

Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs. (Non-interventional prospective patient registry)

Treatment:

Combination Product: Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy

Female and Male

Description:

Diagnosis of cancer scheduled for treatment according to the treating physician's discretion. (Non-interventional patient registry)